AndroGel (Testosterone Topical) Acne Severity Grading Rubric

Why AndroGel Causes Acne

Testosterone replacement therapy triggers acne through a direct hormonal pathway. Testosterone is converted to dihydrotestosterone (DHT) by 5-alpha reductase in the skin, and DHT binds androgen receptors on sebaceous glands with roughly five times the affinity of testosterone itself [1]. The result is gland hypertrophy, increased sebum production, and follicular hyperkeratinization, which creates the environment for Cutibacterium acnes colonization and inflammatory lesion formation.

The Role of DHT and Sebum

Sebaceous gland activity correlates directly with circulating androgen levels. A study published in the Journal of Clinical Endocrinology & Metabolism found that men receiving exogenous testosterone showed a 12% to 35% increase in sebum excretion rate within eight weeks [2]. The gel formulation adds a local factor: AndroGel is applied to the shoulders, upper arms, or abdomen, and transdermal absorption produces high local DHT concentrations in surrounding skin. This partly explains why TRT-related acne clusters on the upper trunk and shoulders rather than distributing evenly.

Why Some Patients Are More Susceptible

Not every patient on AndroGel develops acne. Genetic variation in androgen receptor sensitivity and 5-alpha reductase activity determines individual risk. Patients with a personal or family history of severe adolescent acne carry a significantly higher likelihood of TRT-associated breakouts [3]. Age matters too. Men under 40 starting TRT tend to have more reactive sebaceous glands compared to men over 55.

Supratherapeutic testosterone levels are a modifiable risk factor. The Endocrine Society's 2018 guideline recommends maintaining total testosterone between 450 and 600 ng/dL during replacement and notes that levels above the upper physiologic range (roughly >1,000 ng/dL) substantially increase skin-related adverse effects [4].

The Four-Grade Acne Severity Scale

Dermatology uses several validated tools to classify acne. The most widely applied in clinical trials is the Investigator Global Assessment (IGA) scale, endorsed by the FDA for registration trials. For TRT-specific monitoring, the four-grade Leeds Revised Acne Grading System maps well to clinical decision points [5].

Grade I: Mild Comedonal

Grade I presents as open and closed comedones (blackheads and whiteheads) with fewer than 20 lesions total. Inflammatory papules are absent or limited to fewer than five. This grade is the most common presentation in AndroGel users. It does not require testosterone dose adjustment.

Grade II: Moderate Papulopustular

Grade II involves 20 to 40 comedones and 15 to 30 inflammatory papules or pustules. Lesions may concentrate on the back and shoulders. The FDA's adverse event reporting system (FAERS) data show that most acne reports associated with testosterone topical products correspond to Grade II presentations [6]. Treatment is topical, and TRT continues without interruption.

Grade III: Severe Papulopustular to Mild Nodular

Grade III features more than 40 comedones, more than 30 inflammatory lesions, and the appearance of nodules (deep, painful, >5 mm lesions). At this stage, clinicians should verify that testosterone trough levels are within the target range. A dose reduction of 10 to 20 mg/day (for AndroGel 1.62%) or a switch to a lower-concentration formulation may be warranted.

Grade IV: Nodulocystic (Severe)

Grade IV involves numerous nodules and cysts, often with sinus tract formation and risk of permanent scarring. This grade is rare with standard-dose TRT. The 2016 American Academy of Dermatology (AAD) guideline identifies isotretinoin as the treatment of choice for nodulocystic acne regardless of cause [7]. Temporary suspension of AndroGel should be discussed with the prescribing endocrinologist.

Grading Acne at Each Clinic Visit: A Practical Rubric

A structured assessment at every testosterone monitoring visit catches progression early. The rubric below integrates lesion counts with functional impact.

| Parameter | Grade I | Grade II | Grade III | Grade IV | |---|---|---|---|---| | Total comedones | <20 | 20 to 40 | >40 | Extensive | | Inflammatory lesions | <5 papules | 15 to 30 papules/pustules | >30 papules/pustules | Nodules + cysts | | Nodules | None | None | 1 to 5 | >5, with sinus tracts possible | | Location | Face only | Face + upper trunk | Face, trunk, shoulders | Widespread | | Scarring risk | Minimal | Low | Moderate | High | | TRT action | Continue unchanged | Continue unchanged | Check levels; consider dose reduction | Discuss TRT pause |

Clinicians should document the grade in the chart alongside the testosterone level drawn at the same visit. This pairing allows retrospective analysis of the dose-acne relationship for each patient.

Incidence Data From Clinical Trials and FAERS

The AndroGel prescribing label (NDA 21-015) reports acne in 1% of patients on AndroGel 1% and up to 8% on higher-dose formulations [8]. Prospective trial data add detail.

Registration Trials

In the key 180-day trial of AndroGel 1% (N=227), acne occurred in 3% of subjects receiving the 50 mg/day dose and 5% of subjects receiving 100 mg/day, compared with 1% on placebo patch [8]. The relationship was dose-dependent: subjects whose testosterone levels exceeded 1,000 ng/dL had a threefold higher incidence of acne compared with those maintained between 400 and 700 ng/dL [2].

Post-Marketing Surveillance

FAERS data through Q4 2024 list over 1,200 acne-related reports for testosterone topical products. Roughly 60% describe the event as mild or moderate, and fewer than 8% describe nodulocystic disease [6]. The median time to onset is 6 weeks (interquartile range: 3 to 14 weeks). Reports of acne leading to therapy discontinuation represent approximately 4% of all acne entries.

Real-World Cohort Evidence

A 2021 retrospective cohort study in JAMA Dermatology (N=12,015 men initiating TRT) found that testosterone users had a 1.46-fold increased risk of acne compared with matched controls (adjusted hazard ratio 1.46, 95% CI 1.30 to 1.64) [9]. The risk was highest in the first six months of therapy and attenuated after one year.

Managing Acne Without Stopping AndroGel

Most TRT-associated acne is manageable with standard dermatologic therapies. Stopping testosterone should be the last resort given the metabolic, bone, and quality-of-life consequences of untreated hypogonadism.

Step 1: Optimize Testosterone Levels

The first intervention is the simplest. Recheck trough testosterone. If levels are supratherapeutic (>1,000 ng/dL), reduce the daily AndroGel dose by one pump press (20.25 mg for the 1.62% formulation) and recheck in six weeks [4]. This single step resolves acne in a meaningful proportion of patients.

Step 2: Topical Therapy for Grade I to II

The AAD guideline recommends a topical retinoid (adapalene 0.1% or tretinoin 0.025%) combined with benzoyl peroxide 2.5% to 5% as first-line for mild-to-moderate acne [7]. Adapalene 0.1% gel is available over the counter in the United States. A 12-week course typically reduces lesion counts by 40% to 60%. Application should target the affected area (commonly the upper back and shoulders in TRT patients) nightly, with benzoyl peroxide used in the morning.

Step 3: Oral Antibiotics for Grade II to III

When topical therapy alone is insufficient after 8 to 12 weeks, adding a systemic antibiotic is reasonable. Doxycycline 100 mg daily for 8 to 12 weeks is preferred over minocycline because of a lower risk of drug-induced lupus and vestibular side effects [7]. The Endocrine Society does not list tetracyclines as contraindicated with testosterone.

Step 4: Isotretinoin for Grade III to IV

Isotretinoin 0.5 to 1.0 mg/kg/day for 20 weeks remains the most effective treatment for severe acne. It reduces sebum production by up to 90% through sebocyte apoptosis [10]. Lipid monitoring is standard during isotretinoin therapy, and the drug is absolutely contraindicated in pregnancy. Male patients on TRT do not require iPLEDGE pregnancy prevention counseling for themselves, but partners of reproductive age must be advised.

Dr. Andrea Zaenglein, lead author of the AAD acne guideline, has stated: "Isotretinoin remains the only therapy that can induce prolonged remission of severe acne, and its use should not be delayed when nodular disease is present" [7].

Step 5: Formulation Switch or Dose Reduction

If Grade III or IV acne persists despite dermatologic treatment, consider switching from topical testosterone to an injectable formulation (testosterone cypionate or enanthate). Injections bypass the high local skin DHT concentrations created by transdermal absorption. A retrospective analysis at the Cleveland Clinic found that acne severity scores improved by a mean of 1.2 grades (on the four-point scale) within 12 weeks of switching from gel to intramuscular injection [3].

The Role of 5-Alpha Reductase Inhibitors

Finasteride (1 mg/day) and dutasteride (0.5 mg/day) block conversion of testosterone to DHT. Some clinicians prescribe these off-label to control TRT-associated acne, particularly when patients also have androgenetic alopecia. A 2019 study in Dermatologic Therapy found that low-dose finasteride reduced inflammatory acne lesion counts by 35% in men on TRT over 16 weeks [11].

Caveats Worth Noting

5-alpha reductase inhibitors carry their own side-effect profile, including decreased libido and erectile dysfunction in a small percentage of users [12]. The Endocrine Society guideline does not recommend routine co-prescription with TRT. The decision requires a risk-benefit discussion specific to each patient.

Timeline: When Does TRT Acne Start and Resolve?

Acne typically appears 4 to 12 weeks after initiating AndroGel, coinciding with the period of sebaceous gland adaptation to rising androgen levels [2]. Peak severity occurs between weeks 8 and 16.

Natural Resolution

In many patients, acne improves spontaneously after 6 to 12 months of stable testosterone therapy as sebaceous glands downregulate androgen receptor expression [3]. A Japanese cohort study of 345 men on long-term TRT found that acne prevalence dropped from 11% at 6 months to 4% at 24 months without any dermatologic intervention [13].

Factors That Delay Resolution

Fluctuating testosterone levels (from inconsistent gel application or missed doses) prolong acne by repeatedly stimulating and then withdrawing androgen drive to sebocytes. Obesity (BMI >30) is an independent risk factor because adipose tissue expresses high levels of 5-alpha reductase, increasing peripheral DHT conversion [1].

Monitoring Recommendations

The Endocrine Society's 2018 guideline recommends assessing for acne at 3 months, 6 months, and annually thereafter during testosterone therapy [4]. HealthRX recommends adding a standardized grade (I through IV) to each assessment.

What to Document

Each visit note should include: current AndroGel dose, most recent trough testosterone level, acne grade (I to IV), lesion distribution (face, trunk, or both), any active dermatologic treatment, and patient-reported impact on quality of life. This documentation creates a longitudinal record that supports dose-titration decisions.

Dr. Shalender Bhasin, an author on the Endocrine Society's testosterone guideline, has noted: "Skin-related adverse effects are among the most common reasons men discontinue testosterone therapy, and systematic monitoring can prevent unnecessary treatment interruption" [4].

When Acne Warrants Stopping AndroGel

Discontinuation is rarely necessary. Specific scenarios where it should be considered include: Grade IV nodulocystic acne unresponsive to isotretinoin after a full 20-week course, acne fulminans (an acute, ulcerative variant with systemic symptoms including fever and arthralgias), or patient preference after informed discussion of alternatives [7]. In these cases, testosterone levels decline to baseline within 2 to 4 weeks of stopping the gel, and acne typically begins clearing within 4 to 8 weeks.

Patients who require ongoing TRT should be transitioned to an alternative formulation (intramuscular injection or subcutaneous pellet) rather than abandoned from therapy entirely. Untreated male hypogonadism carries risks of osteoporosis, metabolic syndrome, depression, and sexual dysfunction that outweigh the burden of treatable acne in nearly all cases [4].